quinoxalines has been researched along with Glaucoma in 139 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (15.83) | 18.2507 |
| 2000's | 77 (55.40) | 29.6817 |
| 2010's | 35 (25.18) | 24.3611 |
| 2020's | 5 (3.60) | 2.80 |
| Authors | Studies |
|---|---|
| Chambers, A; Cumpston, KL; Kershner, E; Tobarran, N; Wills, BK | 1 |
| Bigdeli, A; Feghhi, M; Makhmalzadeh, BS; SoleimaniBiatiani, E | 1 |
| Kim, KE; Kim, Y; Lee, CK; Rho, S; Shin, J | 1 |
| Alkahtani, HM; Alomar, AM; Bakheit, AH; Darwish, H | 1 |
| Kurysheva, NI | 2 |
| Aiello, F; Bagetta, G; Cesareo, M; Corasaniti, MT; Nucci, C; Scuteri, D; Tonin, P | 1 |
| Abd-Elgawad, AE; Ibrahim, MM; Jablonski, MM; Soliman, OA | 1 |
| Iotova, V; Kiryazov, K; Stefova, M | 1 |
| Fukuchi, T | 1 |
| Cherukury, M; Durairaj, C; Shen, J | 1 |
| Hallböök, F; Harun-Or-Rashid, M; Lindqvist, N | 1 |
| Harada, C; Harada, T; Kimura, A; Mitamura, Y; Namekata, K; Semba, K | 1 |
| Chew, SK; Goldberg, I; Skalicky, SE | 1 |
| Guzman-Aranguez, A; Loma, P; Perez de Lara, MJ; Pintor, J | 1 |
| Batoosingh, AL; Cantor, LB; Liu, CC; Safyan, E | 1 |
| Agey, P; Dong, CJ; Guo, Y; Hare, WA; Wheeler, L | 1 |
| Motolko, MA | 1 |
| Batiste, C; Fudemberg, SJ; Katz, LJ | 1 |
| Călugăru, D; Călugăru, M | 2 |
| Delgado-Ortega, L; Díaz-Cerezo, S; Pinazo-Durán, MD; Soto-Alvarez, J; Vinuesa-Silva, I; Vinuesa-Silva, JM | 1 |
| Mint, JO; Poling, TR; Schultz, CL | 1 |
| Karczewicz, D; Kuprjanowicz, L | 1 |
| Cheng, JW; Li, Y; Wei, RL | 1 |
| Augustinus, B; De Smet, MD; Hondeghem, K | 1 |
| Earl, M; Nguyen, QH | 1 |
| Campos, JG; Díaz, F; Moreno, M; Pérez de Vargas, I; Vidal, L; Villena, A | 1 |
| Katz, LJ; Razeghinejad, MR; Sawchyn, AK | 1 |
| Montgomery, DM; Rahman, MQ; Ramaesh, K | 1 |
| Adams, BH; Broderick, DF; Menke, DM; Runyan, BR; Shetty, RK; Tun, HW | 1 |
| Dermon, C; Panagis, L; Prokosch, V; Thanos, S; Volk, GF | 1 |
| Alldredge, B; Gerhardt, G; Halverson, K; Pensyl, D; Qualls, C; Sullivan-Mee, M | 1 |
| Artunay, O; Bahcecioglu, H; Rasier, R; Sengul, A; Unal, M; Yuzbasioglu, E | 1 |
| Bernstein, P; Caprioli, J; Schiffman, RM; Spaeth, GL | 1 |
| Hendrikse, F; Peeters, A; Prins, MH; Schouten, JS; Webers, CA | 1 |
| Abdlseaed, AA; Abeysinghe, SS; Kelly, S; Montgomery, DM; Rahman, MQ; Roskell, NS; Shannon, PR | 1 |
| Crichton, A; Fielden, M; Hall, R; Kherani, A; Kherani, F | 1 |
| Maiti, S; Mondol, R; Paul, S; Ray, S; Sa, B | 1 |
| Bhagav, P; Chandran, S; Upadhyay, H | 1 |
| Arriola-Villalobos, P; Díaz-Valle, D; Garcia-Gil-de-Bernabé, J; Iglesias-Lodares, I | 1 |
| Holden, CA; Jadhav, G; Kadam, R; Kompella, UB; Thakur, A; Tyagi, P; Yang, H | 1 |
| Aburahma, MH; Mahmoud, AA | 1 |
| Geethalakshmi, A; Jha, SK; Karki, R; Nikunj, B; Venkatesh, DP | 1 |
| Cottingham, AJ; Hollander, DA; Katz, LJ; Rauchman, SH; Schiffman, RM; Simmons, ST; Williams, JM | 1 |
| Congdon, NG; Friedman, DS; Gilbert, D; Goggins, W; Kader, MA; Krishnadas, R; Quigley, HA; Ramakrishnan, R; Tielsch, J | 1 |
| Chang, TH; Chen, FA; Chien, ST; Horng, CT; Kao, WT; Tsai, MK; Tsai, ML | 1 |
| Inoue, Y; Kaneko, E; Minagawa, Y; Wada, T | 1 |
| Méndez-Hernández, C | 1 |
| Carrasco, MA; Schlaen, BA; Zárate, JO | 1 |
| Holló, G; Kóthy, P | 1 |
| Cho, J; Mullins, CD; Shaya, FT; Wong, W | 1 |
| Baudouin, C; Titouamane, S | 1 |
| Naskar, R; Quinto, K; Schuettauf, F; Zurakowski, D | 1 |
| Phelan, P | 1 |
| Cheng, CY; Chou, JC; Hsu, WM; Ko, YC; Liu, CJ; Liu, JH | 1 |
| Coracas, A; Eckhardt, C; Sauer, S | 1 |
| Kim, P; Lertsumikul, S | 1 |
| Batoosingh, A; Felix, C; Mundorf, T; Whitcup, S; Williams, R | 1 |
| Koren, G; Levin, AV; Mungan, NK; Nischal, KK; Wilson, TW | 1 |
| Fong, JC; Hong, SJ; Wang, HZ; Wu, KY | 1 |
| Lai, R; Wheeler, L; WoldeMussie, E | 1 |
| Chen, MJ; Chou, JC; Hsu, WM; Liu, JH | 1 |
| Mozaffari, E; Reardon, G; Schwartz, GF | 1 |
| Assalian, A; Castilloux, AM; Houde, M; LeLorier, J; Tingey, D | 1 |
| Bowman, RJ; Cope, J; Nischal, KK | 1 |
| Bonini, S; Bucci, MG; Centofanti, M; Manni, G; Oddone, F; Parravano, M; Sacchetti, M | 1 |
| Cunliffe, I; García-Sánchez, J; Landry, J; Pajic, B; Rouland, JF; Spiegel, D; Traverso, C | 1 |
| Becker, HI; Diamant, JI; Walton, RC; Zegans, ME | 1 |
| McKay, IC; Montgomery, DM; Morris, D; Osborne, SA | 1 |
| Appaswamy, S; Bhatt, R; Desai, A; Fitt, A; Sandramouli, S; Whittaker, KW | 1 |
| Ignat, F | 1 |
| Cheng, CY; Hsu, WM; Ko, YC; Liu, CJ | 1 |
| Burnier, MN; Saheb, NE; Saraiva, VS; Solari, HP; Ventura, MP; Vianna, RN | 1 |
| Cheetham, JK; Chou, C; Craven, ER; Schiffman, R; Walters, TR; Williams, R | 1 |
| Al-Jadaan, I; Al-Omran, M; Al-Shahwan, S; Al-Torbak, AA; Edward, DP; Turkmani, S | 1 |
| Susanna, R; Vaidergorn, PG | 1 |
| Márquez-de-Aracena, R; Montero-de-Espinosa, I; Morales, C | 1 |
| Avila, MP; Magacho, L; Queiroz, CF; Reis, R; Santos, LC | 1 |
| Daubert, GP | 1 |
| Jurisić, D; Lacmnovic-Loncar, V; Mandić, Z; Petric, I; Sesar, A; Sesar, I; Tomić, Z | 1 |
| Baudouin, C; Bron, AM; Creuzot-Garcher, C; Lizard, G; Malvitte, L; Montange, T; Vejux, A | 1 |
| Craig, JC; Fung, AT; Healey, PR; Jones, MP; McCluskey, PJ; Reid, SE | 1 |
| Fiscella, R | 1 |
| Feldman, RM | 1 |
| Goñi, FJ | 1 |
| Greenfield, DS; Krupin, T; Liebmann, JM; Ritch, R | 1 |
| Heimann, K; Hoernchen, H; Merz, U; Peschgens, T; Wenzl, T | 1 |
| Craven, ER; Katz, LJ; Simmons, ST | 1 |
| Barnes, D; Ducruet, T; Foerster, V; Hodge, WG; Lachaine, J; Morrison, A; Murray, C; Steffensen, I | 1 |
| Day, DG; Hollander, DA | 1 |
| Craig, JC; Fung, A; Liew, G; Loon, SC; Reid, SE | 1 |
| Serle, JB | 1 |
| Barnebey, HS; Chen, KS; Cinotti, DJ; Coleman, AL; Hersh, SB; Lewis, RA; Morrison, JC; Robin, AL; Walt, J; Zimmerman, TJ | 1 |
| Clevenger, CE; David, R; Henry, JC; Passo, MS; Perell, HF; Siegel, LI; Spaeth, GL; Stamper, RL; Stiles, MC; Walt, JG | 1 |
| Burke, J; Schwartz, M | 1 |
| Hill, R | 1 |
| Greenfield, DS; Liebmann, JM; Ritch, R | 1 |
| Crichton, AC | 1 |
| Gordon, RN; Greenfield, DS; Lama, P; Liebmann, JM; Ritch, R | 1 |
| Hoyng, PF; Rasker, MT | 1 |
| Mermoud, A | 1 |
| Edward, DP; Lark, KK; Pasha, AS; Yan, X | 1 |
| Gebhardt, DO | 1 |
| Burnstein, Y; Robin, AL | 1 |
| Assalian, A; Chevrier, RL; Duperré, J; Lesk, MR | 1 |
| Buys, YM; thoe Schwartzenberg, GW | 1 |
| Grote, A; Korsch, E; Seybold, M; Soditt, V | 1 |
| Barbe, ME; Carlsen, JO; Kwon, YH; Scott, WE; Zabriskie, NA | 1 |
| Hudgins, AC; Pruitt, CA; Sine, C; Stewart, WC | 1 |
| Ainsworth, J; Kulshrestha, M; Ng, S; Roff, E; Sedgwick, G | 1 |
| Carlsson, AM; Chauhan, BC; Leblanc, RP; Lee, AA | 1 |
| Apătăchioae, I; Chiseliţă, D | 1 |
| David, R; Melamed, S | 1 |
| Javitt, JC; Schiffman, RM | 1 |
| Gross, RL; Orengo-Nania, S; Williams, GC | 1 |
| Byles, DB; Frith, P; Salmon, JF | 1 |
| Detry-Morel, M; Dutrieux, C | 1 |
| Gagliuso, DJ; Podos, SM; Serle, JB; Wang, RF | 1 |
| Einarson, TR; Iskedjian, M; Kulin, NA; Tingey, D | 1 |
| Cantor, LB | 1 |
| Lagrèze, WA | 1 |
| Simmons, ST | 1 |
| Chalmers-Redman, RM; Mittag, TW; Podos, SM; Sud, A; Tatton, WG | 1 |
| Chew, P; Lat-Luna, M; Lim, BA; Tan, D; Xiong, X | 1 |
| Ahmed, FA; Chaudhary, P; Hegazy, K; Sharma, SC | 1 |
| Enyedi, LB; Freedman, SF | 1 |
| Maroteaux, I | 1 |
| Grehn, F | 1 |
| Azuara-Blanco, A; Bain, M; Bateman, DN; Clark, R; Forrest, J | 2 |
| Blondeau, P; Rousseau, JA | 1 |
| Katz, LJ | 1 |
| Maurin, JF; May, F; Renard, JP; Rigal-Sastourne, JC | 1 |
| Kasahara, N | 1 |
| Martone, JF; Mead, A; O'Connor, DJ | 1 |
25 review(s) available for quinoxalines and Glaucoma
| Article | Year |
|---|---|
Evidence on the neuroprotective properties of brimonidine in glaucoma.
Topics: Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Quinoxalines; Randomized Controlled Trials as Topic; Vision Disorders; Visual Fields | 2020 |
Brinzolamide plus brimonidine for the treatment of glaucoma: an update.
Topics: Adrenergic alpha-2 Receptor Agonists; Antihypertensive Agents; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Clinical Trials as Topic; Drug Combinations; Glaucoma; Humans; Intraocular Pressure; Quinoxalines; Sulfonamides; Thiazines | 2014 |
Efficacy, safety, and current applications of brimonidine.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Drug Combinations; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Timolol; Treatment Outcome | 2008 |
[Fixed combinations of glaucoma medications].
Topics: Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate; Cloprostenol; Drug Combinations; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Timolol; Travoprost; Treatment Outcome | 2008 |
[Development of conjunctival hyperemia with the use of a fixed combination of latanoprost/timolol: systematic review and meta-analysis of clinical trials].
Topics: Aged; Brimonidine Tartrate; Clinical Trials as Topic; Cloprostenol; Conjunctival Diseases; Cross-Over Studies; Drug Combinations; Drug Therapy, Combination; Glaucoma; Humans; Hyperemia; Latanoprost; Middle Aged; Ocular Hypertension; Odds Ratio; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiazines; Timolol; Travoprost | 2009 |
[Neuroprotection in glaucoma].
Topics: Betaxolol; Brimonidine Tartrate; Disease Progression; Glaucoma; Guanidines; Humans; Memantine; Neuroprotective Agents; Quinoxalines; Sulfonamides; Thiophenes | 2007 |
Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Databases, Factual; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Optic Nerve Diseases; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiazines; Thiophenes; Timolol | 2009 |
Fixed combinations of dorzolamide-timolol and brimonidine-timolol in the management of glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Drug Combinations; Glaucoma; Humans; Intraocular Pressure; Patient Selection; Quinoxalines; Risk Assessment; Sulfonamides; Thiophenes; Timolol; Treatment Outcome | 2010 |
Brimonidine for glaucoma.
Topics: Adrenergic alpha-Agonists; Animals; Antihypertensive Agents; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Quinoxalines | 2010 |
[The latest developments in glaucoma therapy using fixed combination products].
Topics: Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate, Timolol Maleate Drug Combination; Carbonic Anhydrase Inhibitors; Cloprostenol; Drug Combinations; Drug Therapy, Combination; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Latanoprost; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiazines; Thiophenes; Timolol; Travoprost; Treatment Outcome | 2011 |
Reappraising first-line treatment in glaucoma management.
Topics: Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate; Cloprostenol; Dinoprost; Drug Therapy, Combination; Glaucoma; Humans; Latanoprost; Lipids; Prostaglandins; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Travoprost | 2002 |
Role of alpha-2 agonists in neuroprotection.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Glaucoma; Humans; Neuroprotective Agents; Quinoxalines; Receptors, Adrenergic, alpha-2; Retinal Ganglion Cells | 2003 |
Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma.
Topics: Administration, Topical; Aged; Antihypertensive Agents; Brimonidine Tartrate; Female; Glaucoma; Glaucoma, Open-Angle; Humans; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Clinical Trials as Topic; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Male; Ocular Hypertension; Quinoxalines; Sulfonamides; Thiophenes; Treatment Outcome | 2007 |
The efficacy and harm of prostaglandin analogues for IOP reduction in glaucoma patients compared to dorzolamide and brimonidine: a systematic review.
Topics: Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Female; Glaucoma; Humans; Latanoprost; Male; Middle Aged; Prostaglandins F, Synthetic; Prostaglandins, Synthetic; Quinoxalines; Randomized Controlled Trials as Topic; Sulfonamides; Thiophenes; Treatment Outcome | 2008 |
Meta-analysis of randomized controlled trials comparing timolol with brimonidine in the treatment of glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Brimonidine Tartrate; Glaucoma; Humans; Quinoxalines; Randomized Controlled Trials as Topic; Timolol; Treatment Outcome | 2008 |
Pharmacological advances in the treatment of glaucoma.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Clonidine; Ethacrynic Acid; Glaucoma; Humans; Latanoprost; Prostaglandins; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes | 1994 |
Preclinical evaluation of brimonidine.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cats; Cebus; Drug Evaluation, Preclinical; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Rabbits; Rats | 1996 |
Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Betaxolol; Brimonidine Tartrate; Clinical Trials as Topic; Dose-Response Relationship, Drug; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Timolol; Trabeculectomy | 1997 |
[Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].
Topics: Administration, Oral; Administration, Topical; Adrenergic alpha-Agonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Clonidine; Drug Therapy, Combination; Female; Glaucoma; Humans; Latanoprost; Male; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes | 1998 |
[Alpha-2 adrenergic agonists in the treatment of glaucoma].
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Brimonidine Tartrate; Clonidine; Glaucoma; Humans; Intraocular Pressure; Quinoxalines | 1999 |
Meta-analysis of the effect of latanoprost and brimonidine on intraocular pressure in the treatment of glaucoma.
Topics: Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Prostaglandins F, Synthetic; Quinoxalines | 2000 |
The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Glaucoma; Humans; Neuroprotective Agents; Ocular Hypertension; Quinoxalines; Receptors, Adrenergic, alpha-2 | 2000 |
Maintaining mitochondrial membrane impermeability. an opportunity for new therapy in glaucoma?
Topics: Animals; Apoptosis; bcl-X Protein; Brimonidine Tartrate; Cell Membrane Permeability; Glaucoma; Humans; Intraocular Pressure; Mitochondria; Pargyline; Propylamines; Proto-Oncogene Proteins c-bcl-2; Quinoxalines; Retinal Ganglion Cells; Signal Transduction | 2001 |
[New medical treatments of glaucoma. New strategies?].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Drug Therapy, Combination; Glaucoma; Humans; Prostaglandins; Quinoxalines | 2001 |
33 trial(s) available for quinoxalines and Glaucoma
| Article | Year |
|---|---|
Comparisons of efficacy and safety between preserved and preservative-free brimonidine tartrate in glaucoma and ocular hypertension: a parallel-grouped, randomized trial.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Glaucoma; Glaucoma, Open-Angle; Humans; Intraocular Pressure; Ocular Hypertension; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinoxalines; Treatment Outcome | 2023 |
Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Drug Administration Schedule; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Treatment Outcome | 2008 |
Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%-timolol 0.5% therapy.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Brimonidine Tartrate; Conjunctivitis, Allergic; Drug Therapy, Combination; Female; Glaucoma; Humans; Male; Middle Aged; Quinoxalines; Timolol | 2008 |
Fixed-combination brimonidine/timolol as adjunctive therapy to a prostaglandin analog: a 3-month, open-label, replacement study in glaucoma patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Drug Combinations; Drug Hypersensitivity; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Time Factors; Timolol | 2009 |
Bimatoprost 0.03% versus brimonidine 0.2% in the prevention of intraocular pressure spike following neodymium:yttrium–aluminum–garnet laser posterior capsulotomy.
Topics: Aged; Aged, 80 and over; Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate; Capsule Opacification; Cataract; Cloprostenol; Female; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Lasers, Solid-State; Male; Middle Aged; Neodymium; Ocular Hypertension; Ophthalmic Solutions; Posterior Capsule of the Lens; Quinoxalines; Tonometry, Ocular | 2010 |
Control of intraocular pressure and fluctuation with fixed-combination brimonidine-timolol versus brimonidine or timolol monotherapy.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Circadian Rhythm; Double-Blind Method; Drug Combinations; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Quinoxalines; Timolol; Tonometry, Ocular | 2011 |
Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Drug Combinations; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Time Factors; Timolol; Treatment Outcome | 2012 |
A study of initial therapy for glaucoma in southern India: India Glaucoma Outcomes and Treatment (INGOT) Study.
Topics: Aged; Antihypertensive Agents; Antimetabolites, Antineoplastic; Brimonidine Tartrate; Drug Combinations; Female; Fluorouracil; Glaucoma; Humans; India; Intraocular Pressure; Latanoprost; Lens Implantation, Intraocular; Male; Middle Aged; Phacoemulsification; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Surveys and Questionnaires; Thiophenes; Timolol; Tonometry, Ocular; Trabeculectomy; Visual Acuity | 2012 |
Does glaucoma medication influence the diameter of the retinal arteriole in the human eye? (A pilot study using the retinal vessel analyser).
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Arterioles; Betaxolol; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Glaucoma; Humans; Latanoprost; Middle Aged; Ophthalmology; Pilot Projects; Prostaglandins F, Synthetic; Quinoxalines; Retinal Artery; Sulfonamides; Thiazines; Timolol | 2001 |
[Use of brimonidine 0.2% in treatment of glaucoma or ocular hypertony after poorly tolerated beta-blocker treatment].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Appetite; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Patient Satisfaction; Quality of Life; Quinoxalines; Surveys and Questionnaires; Treatment Failure; Treatment Outcome | 2002 |
Effect of latanoprost 0.005% and brimonidine tartrate 0.2% on pulsatile ocular blood flow in normal tension glaucoma.
Topics: Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Cross-Over Studies; Eye; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Prostaglandins F, Synthetic; Pulsatile Flow; Quinoxalines | 2002 |
A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Conjunctiva; Conjunctivitis, Allergic; Dose-Response Relationship, Drug; Double-Blind Method; Glaucoma; Humans; Hyperemia; Intraocular Pressure; Ocular Hypertension; Quinoxalines; Severity of Illness Index | 2003 |
The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Brimonidine Tartrate; Female; Glaucoma; Heart; Humans; Male; Quinoxalines; Retrospective Studies; Timolol | 2003 |
A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure. A six month, evaluator masked, multicentre study in Europe.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Europe; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Middle Aged; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Timolol; Treatment Outcome | 2004 |
Diurnal intraocular pressure and blood pressure with two dosing regimens of brimonidine in normal tension glaucoma.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Blood Pressure; Brimonidine Tartrate; Circadian Rhythm; Drug Administration Schedule; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Quinoxalines | 2004 |
Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Double-Blind Method; Drug Combinations; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Timolol; Treatment Outcome | 2005 |
A randomized, investigator-masked, 4-week study comparing timolol maleate 0.5%, brinzolamide 1%, and brimonidine tartrate 0.2% as adjunctive therapies to travoprost 0.004% in adults with primary open-angle glaucoma or ocular hypertension.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Aged; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Cloprostenol; Double-Blind Method; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Prospective Studies; Quinoxalines; Sulfonamides; Thiazines; Timolol; Travoprost | 2006 |
Visual field and intraocular pressure asymmetry in the low-pressure glaucoma treatment study.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aging; Brimonidine Tartrate; Circadian Rhythm; Double-Blind Method; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Quinoxalines; Timolol; Visual Fields | 2007 |
Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.
Topics: Adult; Aged; Analysis of Variance; Brimonidine Tartrate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Maximum Tolerated Dose; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Organization and Administration; Probability; Prostaglandins F, Synthetic; Quinoxalines; Risk Assessment; Severity of Illness Index; Single-Blind Method; Sulfonamides; Thiazines; Tonometry, Ocular; Treatment Outcome | 2008 |
The efficacy of brimonidine in decreasing elevations in intraocular pressure after laser trabeculoplasty.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Double-Blind Method; Drug Tolerance; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Pharmaceutical Vehicles; Quinoxalines; Trabeculectomy | 1993 |
Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty.
Topics: Adrenergic alpha-Agonists; Adult; Antihypertensive Agents; Brimonidine Tartrate; Double-Blind Method; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines; Trabeculectomy | 1993 |
Lack of cross-reactive allergic response to brimonidine in patients with known apraclonidine allergy.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Clonidine; Cross Reactions; Drug Hypersensitivity; Eye Diseases; Follow-Up Studies; Glaucoma; Humans; Middle Aged; Quinoxalines; Time Factors | 1998 |
Pressure or progression?
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Brimonidine Tartrate; Disease Progression; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Quinoxalines; Timolol; Visual Fields | 1999 |
Apraclonidine 0.5% versus brimonidine 0.2% for the control of intraocular pressure elevation following anterior segment laser procedures.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Anterior Eye Segment; Brimonidine Tartrate; Chronic Disease; Clonidine; Female; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Male; Middle Aged; Observer Variation; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quinoxalines; Trabeculectomy; Treatment Outcome | 1999 |
Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Quinoxalines; Retrospective Studies; Safety; Treatment Outcome | 1999 |
Daily cost of newer glaucoma agents.
Topics: Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Gels; Glaucoma; Humans; Latanoprost; Prostaglandins F, Synthetic; Quinoxalines; Solutions; Sulfonamides; Thiophenes; Timolol | 1999 |
The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension [corrected].
Topics: Administration, Topical; Adrenergic alpha-Agonists; Blood Flow Velocity; Brimonidine Tartrate; Disease Progression; Double-Blind Method; Female; Glaucoma; Humans; Intraocular Pressure; Laser-Doppler Flowmetry; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Retinal Vessels; Visual Fields | 1999 |
Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Brimonidine Tartrate; Double-Blind Method; Female; Glaucoma; Heart Rate; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quinoxalines; Timolol; Vision Tests | 2000 |
Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Blood Pressure; Brimonidine Tartrate; Double-Blind Method; Drug Administration Schedule; Drug Evaluation; Female; Glaucoma; Heart Rate; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Prospective Studies; Quality of Life; Quinoxalines; Safety; Surveys and Questionnaires; Timolol; Treatment Outcome | 2000 |
[Treatment of glaucoma with brimonidine (Alphagan 0.2%)].
Topics: Adolescent; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Child; Drug Therapy, Combination; Female; Glaucoma; Humans; Male; Middle Aged; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines | 2000 |
Efficacy of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers in adult patients with glaucoma or ocular hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Brimonidine Tartrate; Cross-Over Studies; Down-Regulation; Female; Glaucoma; Humans; Immunologic Factors; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Quality of Life; Quinoxalines; Sulfonamides; Thiophenes | 2001 |
Safety and efficacy of brimonidine in children with glaucoma.
Topics: Adolescent; Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; Central Nervous System Diseases; Child; Child, Preschool; Female; Glaucoma; Humans; Intraocular Pressure; Male; Ophthalmic Solutions; Quinoxalines; Safety; Tonometry, Ocular | 2001 |
Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Conjunctivitis, Allergic; Double-Blind Method; Drug Evaluation; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ocular Hypertension; Patient Satisfaction; Preservatives, Pharmaceutical; Quality of Life; Quinoxalines; Safety | 2002 |
81 other study(ies) available for quinoxalines and Glaucoma
| Article | Year |
|---|---|
Systemic toxicity from subcutaneous brimonidine injection successfully treated with naloxone.
Topics: Adrenergic alpha-Agonists; Aged; Analgesics, Opioid; Bradycardia; Brimonidine Tartrate; Drug Overdose; Female; Glaucoma; Humans; Hypotension; Infant; Injections, Subcutaneous; Lethargy; Naloxone; Ophthalmic Solutions; Quinoxalines | 2022 |
Cationic liposomes as promising vehicles for timolol/brimonidine combination ocular delivery in glaucoma: formulation development and in vitro/in vivo evaluation.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Glaucoma; Intraocular Pressure; Liposomes; Polymers; Quinoxalines; Rabbits; Timolol | 2023 |
Brimonidine.
Topics: Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; Glaucoma; Glaucoma, Open-Angle; Humans; Ophthalmic Solutions; Quinoxalines | 2023 |
[Selective α2 agonists in the treatment of glaucoma: neuroprotective properties and impact on ocular blood flow].
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-Agonists; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Quinoxalines | 2019 |
[Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety].
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Ophthalmic Solutions; Quinoxalines | 2019 |
Novel topical ophthalmic formulations for management of glaucoma.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Glaucoma; Lactic Acid; Mice; Nanoparticles; Ophthalmic Solutions; Polyesters; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quinoxalines | 2013 |
Brinzolamide/brimonidine (Simbrinza) for glaucoma.
Topics: Administration, Ophthalmic; Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Drug Combinations; Glaucoma; Humans; Quinoxalines; Sulfonamides; Thiazines | 2013 |
Can ophthalmic drops cause central nervous system depression and cardiogenic shock in infants?
Topics: Absorption; Administration, Ophthalmic; Apnea; Bradycardia; Brimonidine Tartrate; Consciousness Disorders; Dose-Response Relationship, Drug; Drug Combinations; Emergencies; Female; Glaucoma; Humans; Hypothermia; Infant; Muscle Hypotonia; Nasal Mucosa; Ophthalmic Solutions; Quinoxalines; Shock, Cardiogenic; Sulfonamides; Thiazines; Timolol | 2013 |
[Current trend of glaucoma medication with various eye drops].
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Glaucoma; Humans; Latanoprost; Neuroprotective Agents; Ophthalmic Solutions; Ophthalmology; Prostaglandins; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes | 2013 |
Mechanism - based translational pharmacokinetic - pharmacodynamic model to predict intraocular pressure lowering effect of drugs in patients with glaucoma or ocular hypertension.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Dogs; Female; Forecasting; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Models, Biological; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Rabbits; Translational Research, Biomedical; Treatment Outcome | 2014 |
Transactivation of EGF receptors in chicken Müller cells by α2A-adrenergic receptors stimulated by brimonidine.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Blotting, Western; Brimonidine Tartrate; Cells, Cultured; Chick Embryo; Ependymoglial Cells; ErbB Receptors; Glaucoma; Immunohistochemistry; MAP Kinase Signaling System; Quinoxalines; Real-Time Polymerase Chain Reaction; Receptors, Adrenergic, alpha-2; Retina; RNA; Transcriptional Activation | 2014 |
Brimonidine prevents neurodegeneration in a mouse model of normal tension glaucoma.
Topics: Animals; Brimonidine Tartrate; Excitatory Amino Acid Transporter 3; Female; Glaucoma; Humans; Male; Mice; Mice, Knockout; Protective Agents; Quinoxalines; Receptors, N-Methyl-D-Aspartate; Retinal Degeneration; Retinal Ganglion Cells | 2014 |
Diadenosine tetraphosphate improves adrenergic anti-glaucomatous drug delivery and efficiency.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Aqueous Humor; Blotting, Western; Brimonidine Tartrate; Cell Membrane Permeability; Cells, Cultured; Dinucleoside Phosphates; Drug Delivery Systems; Electric Impedance; Epithelium, Corneal; Glaucoma; Humans; Intraocular Pressure; Male; Occludin; Quinoxalines; Rabbits; Tight Junctions; Timolol; Zonula Occludens-1 Protein | 2015 |
Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Calcium; Calcium Signaling; Disease Models, Animal; Excitatory Amino Acid Agonists; Glaucoma; Male; N-Methylaspartate; Neuroprotective Agents; Patch-Clamp Techniques; Phosphodiesterase Inhibitors; Quinoxalines; Rabbits; Rats; Rats, Inbred BN; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, N-Methyl-D-Aspartate; Retina; Retinal Ganglion Cells; Rolipram | 2008 |
A medical device/drug delivery system for treatment of glaucoma.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Brimonidine Tartrate; Chromatography, High Pressure Liquid; Contact Lenses; Drug Delivery Systems; Female; Glaucoma; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Intraocular Pressure; Male; Middle Aged; Quinoxalines; Timolol | 2009 |
Bilateral granulomatous uveitis as a side effect of topical brimonidine: two case reports.
Topics: Administration, Topical; Aged; Aged, 80 and over; Brimonidine Tartrate; Female; Glaucoma; Granuloma; Humans; Ophthalmic Solutions; Quinoxalines; Uveitis | 2009 |
Reaction of Müller cells in an experimental rat model of increased intraocular pressure following timolol, latanoprost and brimonidine.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Disease Models, Animal; Glaucoma; Glial Fibrillary Acidic Protein; Gliosis; Intraocular Pressure; Latanoprost; Male; Neuroglia; Prostaglandins F, Synthetic; Quinoxalines; Rats; Rats, Wistar; Retina; Timolol; Tonometry, Ocular | 2010 |
Use of rituximab for periocular and intraocular mucosa-associated lymphoid tissue lymphoma.
Topics: Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Brimonidine Tartrate; Drug Therapy, Combination; Eye Neoplasms; Female; Glaucoma; Humans; Latanoprost; Loteprednol Etabonate; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Parotid Neoplasms; Prostaglandins F, Synthetic; Quinoxalines; Rituximab; Sulfonamides; Thiophenes; Timolol | 2010 |
Alpha2-adrenergic receptors and their core involvement in the process of axonal growth in retinal explants.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Autoradiography; Axons; Brimonidine Tartrate; Clonidine; Disease Models, Animal; Electrophoresis, Gel, Two-Dimensional; Fluorescent Antibody Technique, Indirect; Glaucoma; Glial Fibrillary Acidic Protein; Optic Nerve Injuries; Organ Culture Techniques; Platelet Activating Factor; Protein Disulfide-Isomerases; Proteomics; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, alpha-2; Receptors, Laminin; Retina; Retinal Degeneration; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Brimonidine Tartrate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Eye; Female; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Quinoxalines; Treatment Outcome | 2010 |
The clinical impact of 2 different strategies for initiating therapy in patients with ocular hypertension.
Topics: Adult; Antihypertensive Agents; Blindness; Brimonidine Tartrate; Decision Trees; Disease Progression; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Markov Chains; Middle Aged; Models, Biological; Monte Carlo Method; Ocular Hypertension; Prostaglandins F, Synthetic; Quinoxalines; Risk Assessment; Sulfonamides; Thiophenes; Timolol | 2011 |
Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database.
Topics: Algorithms; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Clinical Protocols; Databases, Factual; Drug Utilization; Female; Glaucoma; Humans; Male; Ocular Hypertension; Quinoxalines; Scotland; Timolol | 2011 |
Ocular perforation by an acupuncture needle.
Topics: Acupuncture Therapy; Aged; Antihypertensive Agents; Brimonidine Tartrate; Combined Modality Therapy; Eye Injuries, Penetrating; Glaucoma; Humans; Laser Coagulation; Male; Needles; Needlestick Injuries; Quinoxalines; Retina; Retinal Perforations; Timolol; Visual Acuity; Vitrectomy; Vitreous Hemorrhage | 2011 |
Nanovesicular formulation of brimonidine tartrate for the management of glaucoma: in vitro and in vivo evaluation.
Topics: Animals; Brimonidine Tartrate; Chemistry, Pharmaceutical; Cornea; Disease Management; Drug Carriers; Glaucoma; Nanoparticles; Quinoxalines; Rabbits | 2011 |
Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation.
Topics: Acrylic Resins; Administration, Ophthalmic; Adrenergic alpha-2 Receptor Agonists; Animals; Brimonidine Tartrate; Chemistry, Pharmaceutical; Delayed-Action Preparations; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Stability; Glaucoma; Hydrogen-Ion Concentration; Intraocular Pressure; Kinetics; Nanoparticles; Nanotechnology; Quinoxalines; Rabbits; Solubility; Technology, Pharmaceutical | 2011 |
[Pupillary block acute glaucoma due to acrylic intraocular lens posterior dislocation after Nd:YAG capsulotomy].
Topics: Acute Disease; Aged; Brimonidine Tartrate; Combined Modality Therapy; Dipyrone; Drug Therapy, Combination; Emergencies; Female; Furosemide; Glaucoma; Hernia; Humans; Iris; Laser Therapy; Lasers, Solid-State; Lens Capsule, Crystalline; Lens Subluxation; Lenses, Intraocular; Mannitol; Metoclopramide; Postoperative Complications; Pseudophakia; Pupil Disorders; Quinoxalines; Timolol; Vitrectomy; Vitreous Body | 2011 |
Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs.
Topics: Animals; Brimonidine Tartrate; Cattle; Cell Line; Dendrimers; Drug Combinations; Drug Delivery Systems; Epithelium, Corneal; Glaucoma; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Ophthalmic Solutions; Quinoxalines; Timolol | 2012 |
Biodegradable ocular inserts for sustained delivery of brimonidine tartarate: preparation and in vitro/in vivo evaluation.
Topics: Absorbable Implants; Acrylic Resins; Administration, Ophthalmic; Adrenergic alpha-2 Receptor Agonists; Alginates; Animals; Brimonidine Tartrate; Calorimetry, Differential Scanning; Cellulose; Chemistry, Pharmaceutical; Chitosan; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Drug Compounding; Glaucoma; Glucuronic Acid; Hexuronic Acids; Hydrophobic and Hydrophilic Interactions; Hypromellose Derivatives; Intraocular Pressure; Kinetics; Methylcellulose; Ophthalmic Solutions; Polymers; Polymethacrylic Acids; Polyvinyls; Povidone; Quinoxalines; Rabbits; Solubility; Spectroscopy, Fourier Transform Infrared; Technology, Pharmaceutical; X-Ray Diffraction | 2011 |
Sustained ocular delivery of brimonidine tartrate using ion activated in situ gelling system.
Topics: Animals; Biological Availability; Brimonidine Tartrate; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Delivery Systems; Drug Stability; Eye; Gels; Glaucoma; Hydrogen-Ion Concentration; Ions; Ophthalmic Solutions; Polysaccharides, Bacterial; Quinoxalines; Rabbits | 2012 |
The activity of lowering intraocular pressure of cassiae seed extract in a DBA/2J mouse glaucoma model.
Topics: Acetazolamide; Animals; Antihypertensive Agents; Aqueous Humor; Brimonidine Tartrate; Cassia; Chromatography, High Pressure Liquid; Disease Models, Animal; Glaucoma; Glycosides; Intraocular Pressure; L-Lactate Dehydrogenase; Male; Mice; Mice, Inbred DBA; Plant Extracts; Polyphenols; Quinoxalines; Seeds | 2013 |
[Pharmacological profile and clinical efficacy of brimonidine tartrate (AIPHAGAN(®) ophthalmic solution 0.1%)].
Topics: Adrenergic alpha-2 Receptor Agonists; Brimonidine Tartrate; Clinical Trials as Topic; Glaucoma; Humans; Intraocular Pressure; Ophthalmic Solutions; Quinoxalines | 2012 |
[Use of glaucoma medications during pregnancy and breastfeeding].
Topics: Abnormalities, Drug-Induced; Administration, Ophthalmic; Administration, Oral; Adrenergic beta-Antagonists; Animals; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Contraindications; Female; Fetus; Gels; Glaucoma; Humans; Hypotension; Intraocular Pressure; Lactation; Obstetric Labor, Premature; Ophthalmic Solutions; Pregnancy; Pregnancy Complications; Prostaglandins; Quinoxalines; Timolol | 2012 |
Brimonidine-timolol fixed combination induced granulomatous inflammation of the eye.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Conjunctivitis; Drug Therapy, Combination; Female; Glaucoma; Humans; Male; Middle Aged; Quinoxalines; Timolol; Uveitis | 2013 |
Discontinuation rates of topical glaucoma medications in a managed care population.
Topics: Administration, Topical; Adult; Antihypertensive Agents; Brimonidine Tartrate; Chi-Square Distribution; Female; Glaucoma; Humans; Latanoprost; Male; Middle Aged; Ophthalmic Solutions; Patient Compliance; Proportional Hazards Models; Prostaglandins F, Synthetic; Quinoxalines; Retrospective Studies; Survival Analysis; Timolol | 2002 |
Effects of anti-glaucoma medications on ganglion cell survival: the DBA/2J mouse model.
Topics: Aging; Analysis of Variance; Animals; Antihypertensive Agents; Brimonidine Tartrate; Cell Survival; Disease Models, Animal; Glaucoma; Memantine; Mice; Mice, Inbred DBA; Quinoxalines; Retinal Ganglion Cells; Timolol | 2002 |
[Increased myopia and metaporphosia in a 59-year old patient. Serous retinal detachment of the posterior pol after latanoprost administration].
Topics: Antihypertensive Agents; Blood-Retinal Barrier; Brimonidine Tartrate; Diagnosis, Differential; Drug Therapy, Combination; Fluorescein Angiography; Glaucoma; Humans; Latanoprost; Male; Middle Aged; Myopia; Prostaglandins F, Synthetic; Quinoxalines; Retinal Detachment; Visual Acuity | 2003 |
Cystoid macular oedema associated with brimonidine therapy.
Topics: Aged; Antihypertensive Agents; Brimonidine Tartrate; Female; Fluorescein Angiography; Glaucoma; Humans; Macular Edema; Quinoxalines | 2003 |
Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Bradycardia; Brimonidine Tartrate; Female; Glaucoma; Humans; Hypotension; Infant; Infant, Newborn; Intraocular Pressure; Quinoxalines | 2003 |
Effects of commercial antiglaucoma drugs to glutamate-induced [Ca2+)]i increase in cultured neuroblastoma cells.
Topics: Animals; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Calcium; Carteolol; Cell Death; Dose-Response Relationship, Drug; Epinephrine; Glaucoma; Glutamic Acid; Latanoprost; Mice; Neuroblastoma; Neurons; Neuroprotective Agents; Pilocarpine; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiazines; Thiophenes; Timolol; Tumor Cells, Cultured | 2003 |
Patient persistency with pharmacotherapy in the management of glaucoma.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Brimonidine Tartrate; Cohort Studies; Drug Utilization; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Middle Aged; Ocular Hypertension; Patient Compliance; Prostaglandins F, Synthetic; Quinoxalines; Retrospective Studies; Sulfonamides; Thiophenes | 2003 |
Prescription of topical antiglaucoma agents for patients with contraindications to beta-blockers.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Contraindications; Databases, Factual; Drug Prescriptions; Female; Glaucoma; Humans; Latanoprost; Male; Middle Aged; National Health Programs; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quebec; Quinoxalines; Retrospective Studies; Sulfonamides; Thiophenes; Timolol | 2003 |
Ocular and systemic side effects of brimonidine 0.2% eye drops (Alphagan) in children.
Topics: Adolescent; Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; Child; Child, Preschool; Eye Diseases; Female; Glaucoma; Humans; Infant; Infant, Newborn; Male; Ophthalmic Solutions; Quinoxalines; Sleep Stages; Syncope | 2004 |
Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Conjunctivitis, Allergic; Demography; Dermatitis, Allergic Contact; Drug Hypersensitivity; Eyelid Diseases; Female; Glaucoma; Humans; Male; Middle Aged; Ophthalmic Solutions; Quinoxalines; Retrospective Studies; Risk Factors | 2004 |
Anterior uveitis and concurrent allergic conjunctivitis associated with long-term use of topical 0.2% brimonidine tartrate.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Conjunctivitis, Allergic; Female; Glaucoma; Glucocorticoids; Humans; Intraocular Pressure; Male; Ophthalmic Solutions; Prednisolone; Quinoxalines; Uveitis, Anterior | 2004 |
Alphagan allergy may increase the propensity for multiple eye-drop allergy.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Cross Reactions; Drug Administration Schedule; Drug Hypersensitivity; Female; Glaucoma; Glaucoma, Open-Angle; Humans; Longitudinal Studies; Male; Middle Aged; Ophthalmic Solutions; Quinoxalines; Retrospective Studies; Sulfonamides; Thiophenes; Timolol | 2005 |
Prospective survey of adverse reactions to topical antiglaucoma medications in a hospital population.
Topics: Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Female; Filtering Surgery; Glaucoma; Humans; Intraocular Pressure; Male; Middle Aged; Ophthalmic Solutions; Outpatient Clinics, Hospital; Patient Acceptance of Health Care; Prospective Studies; Quinoxalines; Time Factors | 2005 |
[Neuroprotection and vasoprotection in glaucoma].
Topics: Antihypertensive Agents; Betaxolol; Brimonidine Tartrate; Carteolol; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Neuroprotective Agents; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Treatment Outcome | 2004 |
Cost considerations of the new fixed combinations for glaucoma medical therapy.
Topics: Administration, Topical; Antihypertensive Agents; Brimonidine Tartrate; Canada; Drug Combinations; Glaucoma; Humans; Latanoprost; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes; Timolol | 2005 |
Side-effect profile of brimonidine tartrate in children.
Topics: Adolescent; Adrenergic alpha-Agonists; Brimonidine Tartrate; Central Nervous System Diseases; Child; Child, Preschool; Female; Glaucoma; Humans; Infant; Intraocular Pressure; Male; Prospective Studies; Quinoxalines; Risk Factors; Sleep; Sleep Stages; Surveys and Questionnaires | 2005 |
Argon laser trabeculoplasty and reduction of ocular hypotensive medication used by glaucoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Brimonidine Tartrate; Chronic Disease; Circadian Rhythm; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Male; Middle Aged; Quinoxalines; Trabeculectomy; Treatment Outcome | 2006 |
[Ocular hypertension in children treated with brimonidine 0.2%. A clinical study].
Topics: Administration, Topical; Antihypertensive Agents; Brimonidine Tartrate; Child; Female; Glaucoma; Humans; Intraocular Pressure; Male; Ocular Hypertension; Quinoxalines; Retrospective Studies; Treatment Outcome | 2006 |
Is brimonidine ophthalmic a safe therapy for infants?
Topics: Adrenergic alpha-Agonists; Bradycardia; Brimonidine Tartrate; Glaucoma; Humans; Hypotension; Infant; Male; Ophthalmic Solutions; Quinoxalines | 2006 |
[Intraocular pressure after ND: YAG laser capsulotomy in pseudophakic patients with glaucoma].
Topics: Administration, Topical; Antihypertensive Agents; Brimonidine Tartrate; Cataract Extraction; Glaucoma; Humans; Intraocular Pressure; Laser Therapy; Lens Capsule, Crystalline; Preoperative Care; Pseudophakia; Quinoxalines; Sulfonamides; Thiophenes | 2006 |
Measurement of inflammatory cytokines by multicytokine assay in tears of patients with glaucoma topically treated with chronic drugs.
Topics: Administration, Topical; Aged; Amides; Antihypertensive Agents; Bimatoprost; Brimonidine Tartrate; Carteolol; Case-Control Studies; Chemokines; Cloprostenol; Cytokines; Dose-Response Relationship, Immunologic; Drug Therapy, Combination; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Lipids; Male; Prospective Studies; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Tears; Thiophenes; Timolol | 2007 |
Brimonidine/Timolol: a viewpoint by Richard Fiscella.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Quinoxalines; Randomized Controlled Trials as Topic; Timolol; Treatment Outcome | 2006 |
Brimonidine/Timolol: a viewpoint by Robert M. Feldman.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Glaucoma; Humans; Prostaglandins F, Synthetic; Quinoxalines; Timolol | 2006 |
Brimonidine/Timolol: a viewpoint by Francisco J. Goñi.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Quinoxalines; Randomized Controlled Trials as Topic; Sulfonamides; Thiophenes; Timolol; Treatment Outcome | 2006 |
[Depression of respiration via toxic effects on the central nervous system following use of topical brimonidine in an infant with congenital glaucoma].
Topics: Antihypertensive Agents; Apnea; Brimonidine Tartrate; Cataract; Female; Glaucoma; Humans; Infant, Newborn; Infant, Premature, Diseases; Neurotoxicity Syndromes; Ophthalmic Solutions; Postoperative Complications; Quinoxalines; Respiratory Insufficiency; Trabeculectomy | 2007 |
New drug information. Combigan.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Quinoxalines; Timolol | 2008 |
New agents for the treatment of glaucoma.
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Prostaglandins F, Synthetic; Quinoxalines | 1997 |
Brimonidine--an alpha 2-agonist for glaucoma.
Topics: Administration, Topical; Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Brimonidine Tartrate; Clinical Trials as Topic; Contraindications; Glaucoma; Humans; Intraocular Pressure; Quinoxalines; Xerostomia | 1997 |
Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine.
Topics: Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; Clonidine; Glaucoma; Humans; Quinoxalines | 1998 |
[Modern anti-glaucoma drugs and their secondary effects].
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Dinoprost; Glaucoma; Humans; Quinoxalines; Sulfonamides; Thiophenes | 1998 |
The effect of latanoprost and brimonidine on rabbit subconjunctival fibroblasts.
Topics: Adrenergic alpha-Agonists; Animals; Brimonidine Tartrate; Cell Count; Cell Division; Conjunctiva; Disease Models, Animal; Fibroblasts; Glaucoma; Intraocular Pressure; Latanoprost; Microfilament Proteins; Ophthalmic Solutions; Proliferating Cell Nuclear Antigen; Prostaglandins F, Synthetic; Quinoxalines; Rabbits | 1999 |
[Four new drugs for glaucoma: apraclonidine, brimonidine, dorzolamide and latanoprost].
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Clonidine; Drug Approval; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Netherlands; Prostaglandins F, Synthetic; Quinoxalines; Sulfonamides; Thiophenes | 1999 |
Systemic adverse effects of topical treatment with brimonidine in an infant with secondary glaucoma.
Topics: Adrenergic alpha-Agonists; Blood-Brain Barrier; Brimonidine Tartrate; Central Nervous System; Glaucoma; Humans; Infant; Quinoxalines | 1999 |
Apparent central nervous system depression in infants after the use of topical brimonidine.
Topics: Adrenergic alpha-Agonists; Brimonidine Tartrate; Central Nervous System; Follow-Up Studies; Glaucoma; Humans; Infant; Infant, Newborn; Intraocular Pressure; Male; Nervous System Diseases; Ocular Hypertension; Ophthalmic Solutions; Quinoxalines | 1999 |
Demonstration of the reversibility of optic disc topography by scanning laser ophthalmoscopy.
Topics: Adrenergic alpha-Agonists; Aniridia; Brimonidine Tartrate; Child; Drug Therapy, Combination; Glaucoma; Humans; Intraocular Pressure; Lasers; Latanoprost; Male; Ophthalmoscopy; Optic Disk; Optic Nerve Diseases; Prostaglandins F, Synthetic; Quinoxalines; Trabeculectomy; Visual Acuity | 1999 |
Incidence of brimonidine allergy in patients previously allergic to apraclonidine.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Clonidine; Conjunctivitis; Cross Reactions; Dermatitis, Allergic Contact; Drug Hypersensitivity; Female; Glaucoma; Humans; Hyperemia; Incidence; Male; Middle Aged; Quinoxalines; Retrospective Studies; Risk Factors | 2000 |
Anterior uveitis as a side effect of topical brimonidine.
Topics: Acute Disease; Administration, Topical; Adrenergic alpha-Agonists; Aged; Aged, 80 and over; Anterior Eye Segment; Brimonidine Tartrate; Female; Glaucoma; Humans; Intraocular Pressure; Male; Ophthalmic Solutions; Quinoxalines; Recurrence; Uveitis, Anterior; Visual Acuity | 2000 |
Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes.
Topics: Animals; Antihypertensive Agents; Brimonidine Tartrate; Drug Synergism; Drug Therapy, Combination; Female; Glaucoma; Intraocular Pressure; Latanoprost; Macaca fascicularis; Ophthalmic Solutions; Prostaglandins F, Synthetic; Quinoxalines; Random Allocation; Sulfonamides; Thiophenes; Timolol | 2000 |
[Neuroprotection. Bases and possibilities of a future clinical use].
Topics: Adrenergic alpha-Agonists; Animals; Apoptosis; Brimonidine Tartrate; Clinical Trials as Topic; Disease Models, Animal; Dopamine Agents; Eye Diseases; Forecasting; Glaucoma; Humans; Memantine; Neuroprotective Agents; Optic Neuritis; Quinoxalines; Retinal Diseases; Visual Fields | 2001 |
Quantitation of mitomycin C in human ocular tissues by high-performance liquid chromatography-photo-diode array detection.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Chromatography, High Pressure Liquid; Glaucoma; Humans; Mitomycin; Molecular Structure; Premedication; Quinoxalines; Sclera; Timolol; Trabeculectomy | 2001 |
Neuroprotective effect of alpha(2) agonist (brimonidine) on adult rat retinal ganglion cells after increased intraocular pressure.
Topics: Adrenergic alpha-Antagonists; Age Factors; Animals; Brimonidine Tartrate; Cell Count; Cell Survival; Disease Models, Animal; Female; Glaucoma; Intraocular Pressure; Nerve Degeneration; Neuroprotective Agents; Quinoxalines; Rats; Rats, Wistar; Retinal Ganglion Cells; Time Factors | 2001 |
[Experience with topical brimonidine in the treatment of glaucomas].
Topics: Antihypertensive Agents; Brimonidine Tartrate; Glaucoma; Humans; Quinoxalines | 2001 |
[Prospects for neuroprotective glaucoma therapy].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Apoptosis; Betaxolol; Brain-Derived Neurotrophic Factor; Brimonidine Tartrate; Calcium Channel Blockers; Disease Models, Animal; Dopamine Agents; Glaucoma; Glaucoma, Open-Angle; Haplorhini; Humans; Memantine; Neuroprotective Agents; Nimodipine; Nitric Oxide Synthase; Quinoxalines; Receptors, N-Methyl-D-Aspartate | 2001 |
The impact of new drugs on management of glaucoma in Scotland: observational study.
Topics: Adrenergic alpha-Agonists; Antihypertensive Agents; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Drug Utilization; Glaucoma; Humans; Practice Patterns, Physicians'; Prostaglandins, Synthetic; Quinoxalines; Scotland; Trabeculectomy | 2001 |
Allergic reactions to brimonidine in patients treated for glaucoma.
Topics: Adrenergic alpha-Agonists; Aged; Antihypertensive Agents; Brimonidine Tartrate; Conjunctivitis, Allergic; Dermatitis, Allergic Contact; Drug Hypersensitivity; Female; Glaucoma; Humans; Levobunolol; Male; Quinoxalines; Retrospective Studies; Seasons | 2002 |
The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care.
Topics: Administration, Topical; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Drug Costs; Drug Prescriptions; Glaucoma; Humans; Latanoprost; Middle Aged; Miotics; Prostaglandins F, Synthetic; Prostaglandins, Synthetic; Quinoxalines; Retrospective Studies; Scotland; Sulfonamides; Sympathomimetics; Thiophenes; Trabeculectomy | 2002 |
Brimonidine 0.2% to prevent post laser IOP elevation.
Topics: Antihypertensive Agents; Brimonidine Tartrate; Glaucoma; Humans; Intraocular Pressure; Iris; Laser Therapy; Ocular Hypertension; Postoperative Complications; Quinoxalines; Trabeculectomy | 2002 |
Additive intraocular pressure lowering effect of various medications with latanoprost.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Brimonidine Tartrate; Carbonic Anhydrase Inhibitors; Drug Synergism; Female; Glaucoma; Humans; Intraocular Pressure; Latanoprost; Male; Prostaglandins F, Synthetic; Quinoxalines; Retrospective Studies; Sulfonamides; Thiophenes | 2002 |